Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$21.1 - $27.46 $821,718 - $1.07 Million
-38,944 Reduced 65.09%
20,890 $526,000
Q4 2023

Feb 09, 2024

BUY
$24.82 - $32.88 $689,425 - $913,307
27,777 Added 86.65%
59,834 $1.94 Million
Q3 2023

Nov 13, 2023

SELL
$21.97 - $33.8 $1.67 Million - $2.58 Million
-76,185 Reduced 70.38%
32,057 $873,000
Q2 2023

Aug 11, 2023

BUY
$21.44 - $25.15 $2.1 Million - $2.46 Million
97,741 Added 930.78%
108,242 $2.41 Million
Q1 2023

May 12, 2023

SELL
$19.2 - $24.47 $2.28 Million - $2.9 Million
-118,509 Reduced 91.86%
10,501 $227,000
Q4 2022

Feb 10, 2023

BUY
$19.95 - $29.96 $2.38 Million - $3.57 Million
119,319 Added 1231.24%
129,010 $2.62 Million
Q3 2022

Nov 14, 2022

SELL
$24.7 - $29.12 $1.26 Million - $1.48 Million
-50,883 Reduced 84.0%
9,691 $248,000
Q2 2022

Aug 12, 2022

SELL
$17.33 - $25.3 $744,046 - $1.09 Million
-42,934 Reduced 41.48%
60,574 $1.44 Million
Q1 2022

May 16, 2022

SELL
$16.53 - $25.21 $704,095 - $1.07 Million
-42,595 Reduced 29.15%
103,508 $2.33 Million
Q4 2021

Feb 14, 2022

BUY
$17.1 - $23.34 $1.55 Million - $2.11 Million
90,461 Added 162.58%
146,103 $2.89 Million
Q3 2021

Nov 15, 2021

BUY
$19.68 - $22.53 $556,314 - $636,878
28,268 Added 103.27%
55,642 $1.1 Million
Q2 2021

Aug 16, 2021

BUY
$19.97 - $24.43 $344,502 - $421,441
17,251 Added 170.41%
27,374 $602,000
Q1 2021

May 17, 2021

BUY
$23.49 - $30.56 $237,789 - $309,358
10,123 New
10,123 $240,000
Q4 2019

Feb 14, 2020

SELL
$12.06 - $16.96 $261,099 - $367,184
-21,650 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$10.41 - $14.66 $225,376 - $317,389
21,650 New
21,650 $306,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $7.17B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.